Brean Capital Reiterates Buy Rating, Raises PT On Medivation As Xtandi Deserves To Move Upstream

By: via Benzinga
In a report published Wednesday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Medivation, Inc. (NASDAQ: MDVN), and ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.